Exact Mass: 728.3900435999999

Exact Mass Matches: 728.3900435999999

Found 157 metabolites which its exact mass value is equals to given mass value 728.3900435999999, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Avermectin A1b monosaccharide

Avermectin A1b monosaccharide

C41H60O11 (728.413541)


   

Avermectin MS

Avermectin B1a monosaccharide

C41H60O11 (728.413541)


   

Hordatine A glucoside

N-(4-Carbamimidamidobutyl)-5-[(1Z)-2-[(4-carbamimidamidobutyl)-C-hydroxycarbonimidoyl]eth-1-en-1-yl]-7-hydroxy-2-(4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2,3-dihydro-1-benzofuran-3-carboximidate

C34H48N8O10 (728.3493228)


Hordatine A glucoside is found in cereals and cereal products. Hordatine A glucoside is a component of Hordatine M from barley (see above

   

Boc-phepsi(CH(OH)CH2)phe-val-phe-morpholine

2-Benzyl-5-{[(tert-butoxy)(hydroxy)methylidene]amino}-4-hydroxy-N-(2-methyl-1-{[1-(morpholin-4-yl)-1-oxo-3-phenylpropan-2-yl]-C-hydroxycarbonimidoyl}propyl)-6-phenylhexanimidate

C42H56N4O7 (728.4148786000001)


   

PA(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-(pentadecanoyloxy)-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one pentadecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0)

[(2R)-2-(pentadecanoyloxy)-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of pentadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(12-methyltetradecanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

[(2R)-2-[(12-methyltetradecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(13-methyltetradecanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

[(2R)-2-[(13-methyltetradecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C38H65O11P (728.426427)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2S)-2,3-dihydroxypropoxy][(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2S)-2,3-dihydroxypropoxy][(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2S)-2,3-dihydroxypropoxy][(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2S)-2,3-dihydroxypropoxy][(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2S)-2,3-dihydroxypropoxy][(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2S)-2,3-dihydroxypropoxy][(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

PG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

[(2S)-2,3-dihydroxypropoxy][(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphinic acid

C38H65O11P (728.426427)


PG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

   

3'-O-beta-D-glucopyranosyl-2'-O-isovaleryl-2beta-(2-desoxy-atractyligenin)-beta-D-glucopyranoside

(1R,4R,5R,7R,9R,10S,13R,15S)-15-hydroxy-7-{[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-[(3-methylbutanoyl)oxy]-4-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9-methyl-14-methylidenetetracyclo[11.2.1.0^{1,10}.0^{4,9}]hexadecane-5-carboxylic acid

C36H56O15 (728.3619026)


   
   
   
   
   

(3beta)-3-O-(sulfo)lup-20(29)-en-23,28-dioic acid 28-O-beta-D-glucopyranosyl ester|gypsophilinoside

(3beta)-3-O-(sulfo)lup-20(29)-en-23,28-dioic acid 28-O-beta-D-glucopyranosyl ester|gypsophilinoside

C36H56O13S (728.3441446)


   

2-O-(6-O-hexanoyl-beta-D-glucopyranosyl)-6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose|nonioside H

2-O-(6-O-hexanoyl-beta-D-glucopyranosyl)-6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose|nonioside H

C32H56O18 (728.3466476000001)


   
   

(3beta)-3-[(2-O-sulfo-beta-D-glucopyranosyl)oxy]urs-12-en-22,28-dioic acid|3-O-[beta-D-(2-O-sulphonyl)glucopyranosyl]quinovic acid

(3beta)-3-[(2-O-sulfo-beta-D-glucopyranosyl)oxy]urs-12-en-22,28-dioic acid|3-O-[beta-D-(2-O-sulphonyl)glucopyranosyl]quinovic acid

C36H56O13S (728.3441446)


   
   
   
   
   

(1beta,2alpha,3beta)-2,3-Bis(4-hydroxybenzoyl):1,2,3-Trihydroxy-14-taraxeren-28-oic acid

(1beta,2alpha,3beta)-2,3-Bis(4-hydroxybenzoyl):1,2,3-Trihydroxy-14-taraxeren-28-oic acid

C44H56O9 (728.3924126000001)


   

3?-O-beta-D-glucopyranosyl-2?-O-isovaleryl-2beta-(2-desoxy-atractyligenin)-beta-D-glucopyranoside

3?-O-beta-D-glucopyranosyl-2?-O-isovaleryl-2beta-(2-desoxy-atractyligenin)-beta-D-glucopyranoside

C36H56O15 (728.3619026)


   
   

2??,3??-(22R)-Trihydroxycholestan-6-one-22-O-??-D-glucopyranosyl-(1鈥樏傗垎2)-??-L-arabinopyranoside

2??,3??-(22R)-Trihydroxycholestan-6-one-22-O-??-D-glucopyranosyl-(1鈥樏傗垎2)-??-L-arabinopyranoside

C38H64O13 (728.4346694)


   

3-O-sulfoquillaic acid 28-beta-glucopyranosyl ester

3-O-sulfoquillaic acid 28-beta-glucopyranosyl ester

C36H56O13S (728.3441446)


   

(22S)-1beta-[(beta-D-glucopyranosyl)oxy]-3beta,22-dihydroxycholest-5-en-16beta-yl beta-D-apiofuranoside

(22S)-1beta-[(beta-D-glucopyranosyl)oxy]-3beta,22-dihydroxycholest-5-en-16beta-yl beta-D-apiofuranoside

C38H64O13 (728.4346694)


   
   

Ouabain

Ouabain Octahydrate

C29H60O20 (728.367776)


Ouabain Octahydrate is an inhibitor of Na+/K+-ATPase, used for the treatment of congestive heart failure. Ouabain Octahydrate is an inhibitor of Na+/K+-ATPase, used for the treatment of congestive heart failure.

   

P-TolyltriPhenylPhosPhonium tetra-P-tolylborate

P-TolyltriPhenylPhosPhonium tetra-P-tolylborate

C53H50BP (728.374298)


   
   

Ethyl (2-butyl-4-methyl-6-oxo-1-{[2-(1-trityl-1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1,6-dihydro-5-pyrimidinyl)acetate

Ethyl (2-butyl-4-methyl-6-oxo-1-{[2-(1-trityl-1H-tetrazol-5-yl)-4-biphenylyl]methyl}-1,6-dihydro-5-pyrimidinyl)acetate

C46H44N6O3 (728.3474714)


   

tert-butyl N-[5-benzyl-3-hydroxy-6-[[3-methyl-1-[(1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl)amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate

tert-butyl N-[5-benzyl-3-hydroxy-6-[[3-methyl-1-[(1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl)amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate

C42H56N4O7 (728.4148786000001)


   

[(2S,3R,4S,6R)-2-[[(1R,2S,3R,6E,8S,9S,10S,12R,14E,16S)-3-ethyl-2-hydroxy-2-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-8,10,12-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-dien-9-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-dimethylazanium

[(2S,3R,4S,6R)-2-[[(1R,2S,3R,6E,8S,9S,10S,12R,14E,16S)-3-ethyl-2-hydroxy-2-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-8,10,12-trimethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-dien-9-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-dimethylazanium

C37H62NO13+ (728.4220942)


   

PG(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

PG(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C38H65O11P (728.426427)


   

PG(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

PG(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

C38H65O11P (728.426427)


   

PG(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

PG(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C38H65O11P (728.426427)


   

PG(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

PG(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

C38H65O11P (728.426427)


   

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C38H65O11P (728.426427)


   

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

C38H65O11P (728.426427)


   

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PG(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C38H65O11P (728.426427)


   

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

PG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

C38H65O11P (728.426427)


   

PG(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PG(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C38H65O11P (728.426427)


   

PG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

PG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

C38H65O11P (728.426427)


   

PG(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PG(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C38H65O11P (728.426427)


   

PG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

PG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

C38H65O11P (728.426427)


   

PA(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C38H65O11P (728.426427)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/15:0)

C38H65O11P (728.426427)


   

PA(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C38H65O11P (728.426427)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

C38H65O11P (728.426427)


   

PA(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C38H65O11P (728.426427)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

C38H65O11P (728.426427)


   

3-O-beta-D-glucopyranosyl-2-O-isovaleryl-2beta-(2-desoxy-atractyligenin)-beta-D-glucopyranoside

3-O-beta-D-glucopyranosyl-2-O-isovaleryl-2beta-(2-desoxy-atractyligenin)-beta-D-glucopyranoside

C36H56O15 (728.3619026)


   
   
   
   
   
   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C36H57O13P (728.3536601999999)


   
   

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C36H56O15 (728.3619026)


   

3-[(1S,3R,5S,8R,9S,10R,11R,13R,14S,17S)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3S,4R,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one;octahydrate

3-[(1S,3R,5S,8R,9S,10R,11R,13R,14S,17S)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3S,4R,5R,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one;octahydrate

C29H60O20 (728.367776)


   

[(2S,3S,6S)-6-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C37H60O12S (728.380528)


   

[(2S,3S,6S)-6-[3-dodecanoyloxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[3-dodecanoyloxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C37H60O12S (728.380528)


   

[(2S,3S,6S)-6-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C37H60O12S (728.380528)


   

[(2S,3S,6S)-6-[3-[(E)-dodec-5-enoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[3-[(E)-dodec-5-enoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C37H60O12S (728.380528)


   

[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C36H57O13P (728.3536601999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(2r)-3-{[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-c-hydroxycarbonimidoyl}-2-methylpropanoic acid

(2r)-3-{[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-c-hydroxycarbonimidoyl}-2-methylpropanoic acid

C38H52N2O12 (728.3520072)


   

(1r,3ar,5r,5ar,5br,7ar,9s,11as,11br,12r,13ar,13bs)-9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

(1r,3ar,5r,5ar,5br,7ar,9s,11as,11br,12r,13ar,13bs)-9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

C45H60O8 (728.428796)


   

(1s,1's,2s,2's,5s,5'r,8'r,9s,9's,10's,11'r,12r,13s,14s,15r,15's,18'r,19s,22r)-9',10',13,14,15',18',19,22-octahydroxy-12',12',16,16-tetramethyl-10,17',21-trioxaspiro[hexacyclo[11.6.2.1⁵,¹².0¹,¹⁵.0²,¹².0⁶,¹¹]docosane-9,6'-pentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan]-6(11)-en-7'-one

(1s,1's,2s,2's,5s,5'r,8'r,9s,9's,10's,11'r,12r,13s,14s,15r,15's,18'r,19s,22r)-9',10',13,14,15',18',19,22-octahydroxy-12',12',16,16-tetramethyl-10,17',21-trioxaspiro[hexacyclo[11.6.2.1⁵,¹².0¹,¹⁵.0²,¹².0⁶,¹¹]docosane-9,6'-pentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan]-6(11)-en-7'-one

C40H56O12 (728.3771576)


   

2-[(2s,8s,11s,14r,17s)-17-[(2r)-butan-2-yl]-3,6,9,12,15,18-hexahydroxy-8-(2-{2-[(hydroxymethylidene)amino]phenyl}-2-oxoethyl)-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[(2s,8s,11s,14r,17s)-17-[(2r)-butan-2-yl]-3,6,9,12,15,18-hexahydroxy-8-(2-{2-[(hydroxymethylidene)amino]phenyl}-2-oxoethyl)-11,14-bis(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C35H52N8O9 (728.3857062000001)


   

(2r,3r,4s,5s,6r)-2-{[(1r,2s,3as,3bs,7r,9r,9ar,9bs,11as)-2-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-7-hydroxy-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(1r,2s,3as,3bs,7r,9r,9ar,9bs,11as)-2-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-7-hydroxy-1-[(2s,3s)-3-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C38H64O13 (728.4346694)


   

2α,3β-(22r)-trihydroxycholestan-6-one-22-o-β-d-glucopyranosyl-(1→2)-α-l-arabinopyra-noside

NA

C38H64O13 (728.4346694)


{"Ingredient_id": "HBIN005201","Ingredient_name": "2\u03b1,3\u03b2-(22r)-trihydroxycholestan-6-one-22-o-\u03b2-d-glucopyranosyl-(1\u21922)-\u03b1-l-arabinopyra-noside","Alias": "NA","Ingredient_formula": "C38H64O13","Ingredient_Smile": "CC(C)CCC(C(C)C1CCC2C1(CCC3C2CC(=O)C4C3(CC(C(C4)O)O)C)C)OC5C(C(C(CO5)O)O)OC6C(C(C(C(O6)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21679","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s)-7-(2-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

(1s)-7-(2-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C42H52N2O9 (728.3672622000001)


   

3-{[2-({[4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-c-hydroxycarbonimidoyl}-2-methylpropanoic acid

3-{[2-({[4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-c-hydroxycarbonimidoyl}-2-methylpropanoic acid

C38H52N2O12 (728.3520072)


   

10-{[4,5-dihydroxy-6-(hydroxymethyl)-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

10-{[4,5-dihydroxy-6-(hydroxymethyl)-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O13S (728.3441446)


   

9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

C45H60O8 (728.428796)


   

16-methyl-11-[1-(tetradecanoyloxy)ethyl]-1,6,13,22-tetraazaheptacyclo[15.11.1.0²,¹⁵.0⁵,¹⁴.0⁷,¹².0²¹,²⁹.0²³,²⁸]nonacosa-2(15),3,5,7,9,11,13,17,19,21(29),23,25,27-tridecaene-4,24-dicarboxylic acid

16-methyl-11-[1-(tetradecanoyloxy)ethyl]-1,6,13,22-tetraazaheptacyclo[15.11.1.0²,¹⁵.0⁵,¹⁴.0⁷,¹².0²¹,²⁹.0²³,²⁸]nonacosa-2(15),3,5,7,9,11,13,17,19,21(29),23,25,27-tridecaene-4,24-dicarboxylic acid

C44H48N4O6 (728.3573667999999)


   

(1s,3as,5ar,5br,7ar,8s,9s,11ar,11br,13as,13bs)-5a,5b,8,13b-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

(1s,3as,5ar,5br,7ar,8s,9s,11ar,11br,13as,13bs)-5a,5b,8,13b-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

C36H56O13S (728.3441446)


   

6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl 2-[2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl 2-[2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C41H60O11 (728.413541)


   

2-[3,6,9,12,15,18-hexahydroxy-8-(2-{2-[(hydroxymethylidene)amino]phenyl}-2-oxoethyl)-11,14-bis(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

2-[3,6,9,12,15,18-hexahydroxy-8-(2-{2-[(hydroxymethylidene)amino]phenyl}-2-oxoethyl)-11,14-bis(2-methylpropyl)-17-(sec-butyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1(18),3,6,9,12,15-hexaen-2-yl]ethanimidic acid

C35H52N8O9 (728.3857062000001)


   

(1r,3ar,5s,5ar,5br,7ar,9s,11as,11br,12r,13ar,13br)-9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

(1r,3ar,5s,5ar,5br,7ar,9s,11as,11br,12r,13ar,13br)-9-hydroxy-5-(4-hydroxybenzoyloxy)-3a,5a,5b,8,8,11a-hexamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-12-yl 4-hydroxy-3-methoxybenzoate

C45H60O8 (728.428796)


   

(1s,3as,3br,5as,7r,8r,9ar,9bs,11ar)-1-[(2s,3s)-3-{[(2r,3s,4r,5s)-4,5-dihydroxy-3-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methylheptan-2-yl]-7,8-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

(1s,3as,3br,5as,7r,8r,9ar,9bs,11ar)-1-[(2s,3s)-3-{[(2r,3s,4r,5s)-4,5-dihydroxy-3-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methylheptan-2-yl]-7,8-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

C38H64O13 (728.4346694)


   

7-{2-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-4,5-dimethoxyphenoxy}-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

7-{2-[(6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-4,5-dimethoxyphenoxy}-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C42H52N2O9 (728.3672622000001)


   

[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

C36H56O13S (728.3441446)


   

2-[(8-{[9a-formyl-3a,5a-dihydroxy-11a-methyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

2-[(8-{[9a-formyl-3a,5a-dihydroxy-11a-methyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

C38H56N4O10 (728.3996236)


   

28-hydroxy-4,20-bis(3-hydroxy-2-methylhex-4-en-2-yl)-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

28-hydroxy-4,20-bis(3-hydroxy-2-methylhex-4-en-2-yl)-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

C42H52N2O9 (728.3672622000001)


   

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-10-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(sulfooxy)oxan-2-yl]oxy}-1,2,6b,9,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O13S (728.3441446)


   

(4s,6z,8z,10e,12z,20s,22z,24z,26e,28r)-28-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

(4s,6z,8z,10e,12z,20s,22z,24z,26e,28r)-28-hydroxy-4,20-bis[(3s,4e)-3-hydroxy-2-methylhex-4-en-2-yl]-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

C42H52N2O9 (728.3672622000001)


   

5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

C36H56O13S (728.3441446)


   

(6z,8z,10z,12z,22z,24z,26z)-28-hydroxy-4,20-bis[(4e)-3-hydroxy-2-methylhex-4-en-2-yl]-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

(6z,8z,10z,12z,22z,24z,26z)-28-hydroxy-4,20-bis[(4e)-3-hydroxy-2-methylhex-4-en-2-yl]-3,15,19,31-tetraoxa-33,34-diazatricyclo[28.2.1.1¹⁴,¹⁷]tetratriaconta-1(32),6,8,10,12,14(34),16,22,24,26,30(33)-undecaene-2,18-dione

C42H52N2O9 (728.3672622000001)


   

(1r,3as,5ar,5br,7ar,8s,9s,11ar,11br,13ar,13br)-5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

(1r,3as,5ar,5br,7ar,8s,9s,11ar,11br,13ar,13br)-5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-9-(sulfooxy)-3a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-hexadecahydrocyclopenta[a]chrysene-8-carboxylic acid

C36H56O13S (728.3441446)


   

9',10',13,14,15',18',19,22-octahydroxy-12',12',16,16-tetramethyl-10,17',21-trioxaspiro[hexacyclo[11.6.2.1⁵,¹².0¹,¹⁵.0²,¹².0⁶,¹¹]docosane-9,6'-pentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan]-6(11)-en-7'-one

9',10',13,14,15',18',19,22-octahydroxy-12',12',16,16-tetramethyl-10,17',21-trioxaspiro[hexacyclo[11.6.2.1⁵,¹².0¹,¹⁵.0²,¹².0⁶,¹¹]docosane-9,6'-pentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan]-6(11)-en-7'-one

C40H56O12 (728.3771576)


   

(2s,3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(2s,3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C41H60O11 (728.413541)


   

3-({6-[(hexanoyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-4,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl octanoate

3-({6-[(hexanoyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-4,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl octanoate

C32H56O18 (728.3466476000001)


   

1-[5-({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl}oxy)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

1-[5-({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl}oxy)-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

C38H64O13 (728.4346694)


   

(2s)-2-[(8-{[(1r,3as,3br,5as,7s,9as,9bs,11ar)-9a-formyl-3a,5a-dihydroxy-11a-methyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

(2s)-2-[(8-{[(1r,3as,3br,5as,7s,9as,9bs,11ar)-9a-formyl-3a,5a-dihydroxy-11a-methyl-1-(6-oxopyran-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-1-hydroxy-8-oxooctylidene)amino]-5-carbamimidamidopentanoic acid

C38H56N4O10 (728.3996236)


   

1-{3-[(4,5-dihydroxy-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methylheptan-2-yl}-7,8-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

1-{3-[(4,5-dihydroxy-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methylheptan-2-yl}-7,8-dihydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

C38H64O13 (728.4346694)


   

(3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

(3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl (2r)-2-[(1r,2r,3ar,5ar,9as,11ar)-2-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoate

C41H60O11 (728.413541)


   

(1r,4r,5r,7r,9r,10s,13r,15s)-15-hydroxy-7-{[(3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3-[(3-methylbutanoyl)oxy]-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9-methyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid

(1r,4r,5r,7r,9r,10s,13r,15s)-15-hydroxy-7-{[(3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3-[(3-methylbutanoyl)oxy]-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9-methyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid

C36H56O15 (728.3619026)


   

(1r)-7-(5-{[(1s)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2,3-dimethoxyphenoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-7-(5-{[(1s)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-2,3-dimethoxyphenoxy)-1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline

C42H52N2O9 (728.3672622000001)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-4-methoxy-4-oxobutanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-4-methoxy-4-oxobutanimidic acid

C38H52N2O12 (728.3520072)


   

2-[(2-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-7-hydroxy-1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(2-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-7-hydroxy-1-(3-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C38H64O13 (728.4346694)


   

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-{[(2s,3r,4s,5r)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-{[(2s,3r,4s,5r)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-6-methylhept-3-en-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

C38H64O13 (728.4346694)


   

[4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

[4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

C36H56O13S (728.3441446)


   

(2s,3r,4s,5s,6r)-3-{[(2s,3r,4s,5s,6r)-6-[(hexanoyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-4,5-dihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl octanoate

(2s,3r,4s,5s,6r)-3-{[(2s,3r,4s,5s,6r)-6-[(hexanoyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}-4,5-dihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl octanoate

C32H56O18 (728.3466476000001)